First known case of catatonia due to cyclosporine A-related neurotoxicity in a pediatric patient with steroid-resistant nephrotic syndrome

Abstract Background Catatonia is a neuropsychiatric syndrome characterized by diverse psychomotor abnormalities, including motor dysregulation and behavioral and affective disturbances. Once thought to occur primarily in the context of schizophrenia, recent data suggest most cases of catatonia devel...

Full description

Bibliographic Details
Main Authors: R. David Heekin, Kalonda Bradshaw, Chadi A. Calarge
Format: Article
Language:English
Published: BMC 2019-04-01
Series:BMC Psychiatry
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12888-019-2107-6
_version_ 1817994988680642560
author R. David Heekin
Kalonda Bradshaw
Chadi A. Calarge
author_facet R. David Heekin
Kalonda Bradshaw
Chadi A. Calarge
author_sort R. David Heekin
collection DOAJ
description Abstract Background Catatonia is a neuropsychiatric syndrome characterized by diverse psychomotor abnormalities, including motor dysregulation and behavioral and affective disturbances. Once thought to occur primarily in the context of schizophrenia, recent data suggest most cases of catatonia develop in individuals with depressive or bipolar disorders. Moreover, catatonia may ensue in general medical and neurological conditions, as well as due to a variety of pharmaceuticals, drugs of abuse, and toxic agents. At one time considered rare in pediatric patients, evidence now suggests catatonia is both underrecognized and undertreated in this population, where it carries an elevated risk of morbidity and mortality. Here we present the case of a child with steroid-resistant nephrotic syndrome who developed catatonia due to cyclosporine A-related neurotoxicity. Case presentation A 9-year-old African-American boy with no psychiatric history and a 9-month history of nephrotic syndrome due to focal segmental glomerulosclerosis was admitted to the local children’s hospital for management of mutism, posturing, insomnia, gait abnormalities, and somatic delusions. Seven days prior to admission, his cyclosporine plasma concentration was elevated at 1224 ng/mL (therapeutic range: 100–200 ng/mL). Upon admission, cyclosporine was discontinued and psychiatry was consulted, diagnosing catatonia. The patient subsequently received propofol 80 mg IV resulting in a transient lysis of catatonia. Over a lengthy hospitalization, the patient’s catatonia was initially treated with lorazepam, quetiapine being added later to target psychosis. All signs and symptoms of catatonia resolved, and the patient was eventually tapered off both lorazepam and quetiapine with no return of symptoms more than 6 months later. Conclusions To our knowledge, this case represents the first reported instance of cyclosporine A-induced catatonia in a patient with steroid-resistant nephrotic syndrome. It illustrates the importance of maintaining vigilance for signs and symptoms of cyclosporine A-related neurotoxicity (including catatonia) in patients with steroid-resistant nephrotic syndrome. In addition, it highlights the challenges faced by clinicians in jurisdictions that prohibit the use of electroconvulsive therapy in pediatric patients.
first_indexed 2024-04-14T02:00:26Z
format Article
id doaj.art-b41a0f6a12ef4474af5ac96bdcd5b317
institution Directory Open Access Journal
issn 1471-244X
language English
last_indexed 2024-04-14T02:00:26Z
publishDate 2019-04-01
publisher BMC
record_format Article
series BMC Psychiatry
spelling doaj.art-b41a0f6a12ef4474af5ac96bdcd5b3172022-12-22T02:18:52ZengBMCBMC Psychiatry1471-244X2019-04-011911810.1186/s12888-019-2107-6First known case of catatonia due to cyclosporine A-related neurotoxicity in a pediatric patient with steroid-resistant nephrotic syndromeR. David Heekin0Kalonda Bradshaw1Chadi A. Calarge2Department of Psychiatry and Behavioral Sciences, Baylor College of MedicineUniversity of Texas Health Science Center at HoustonDepartment of Psychiatry and Behavioral Sciences, Baylor College of MedicineAbstract Background Catatonia is a neuropsychiatric syndrome characterized by diverse psychomotor abnormalities, including motor dysregulation and behavioral and affective disturbances. Once thought to occur primarily in the context of schizophrenia, recent data suggest most cases of catatonia develop in individuals with depressive or bipolar disorders. Moreover, catatonia may ensue in general medical and neurological conditions, as well as due to a variety of pharmaceuticals, drugs of abuse, and toxic agents. At one time considered rare in pediatric patients, evidence now suggests catatonia is both underrecognized and undertreated in this population, where it carries an elevated risk of morbidity and mortality. Here we present the case of a child with steroid-resistant nephrotic syndrome who developed catatonia due to cyclosporine A-related neurotoxicity. Case presentation A 9-year-old African-American boy with no psychiatric history and a 9-month history of nephrotic syndrome due to focal segmental glomerulosclerosis was admitted to the local children’s hospital for management of mutism, posturing, insomnia, gait abnormalities, and somatic delusions. Seven days prior to admission, his cyclosporine plasma concentration was elevated at 1224 ng/mL (therapeutic range: 100–200 ng/mL). Upon admission, cyclosporine was discontinued and psychiatry was consulted, diagnosing catatonia. The patient subsequently received propofol 80 mg IV resulting in a transient lysis of catatonia. Over a lengthy hospitalization, the patient’s catatonia was initially treated with lorazepam, quetiapine being added later to target psychosis. All signs and symptoms of catatonia resolved, and the patient was eventually tapered off both lorazepam and quetiapine with no return of symptoms more than 6 months later. Conclusions To our knowledge, this case represents the first reported instance of cyclosporine A-induced catatonia in a patient with steroid-resistant nephrotic syndrome. It illustrates the importance of maintaining vigilance for signs and symptoms of cyclosporine A-related neurotoxicity (including catatonia) in patients with steroid-resistant nephrotic syndrome. In addition, it highlights the challenges faced by clinicians in jurisdictions that prohibit the use of electroconvulsive therapy in pediatric patients.http://link.springer.com/article/10.1186/s12888-019-2107-6CatatoniaNephrotic syndromeCyclosporineNeurotoxicityPropofol
spellingShingle R. David Heekin
Kalonda Bradshaw
Chadi A. Calarge
First known case of catatonia due to cyclosporine A-related neurotoxicity in a pediatric patient with steroid-resistant nephrotic syndrome
BMC Psychiatry
Catatonia
Nephrotic syndrome
Cyclosporine
Neurotoxicity
Propofol
title First known case of catatonia due to cyclosporine A-related neurotoxicity in a pediatric patient with steroid-resistant nephrotic syndrome
title_full First known case of catatonia due to cyclosporine A-related neurotoxicity in a pediatric patient with steroid-resistant nephrotic syndrome
title_fullStr First known case of catatonia due to cyclosporine A-related neurotoxicity in a pediatric patient with steroid-resistant nephrotic syndrome
title_full_unstemmed First known case of catatonia due to cyclosporine A-related neurotoxicity in a pediatric patient with steroid-resistant nephrotic syndrome
title_short First known case of catatonia due to cyclosporine A-related neurotoxicity in a pediatric patient with steroid-resistant nephrotic syndrome
title_sort first known case of catatonia due to cyclosporine a related neurotoxicity in a pediatric patient with steroid resistant nephrotic syndrome
topic Catatonia
Nephrotic syndrome
Cyclosporine
Neurotoxicity
Propofol
url http://link.springer.com/article/10.1186/s12888-019-2107-6
work_keys_str_mv AT rdavidheekin firstknowncaseofcatatoniaduetocyclosporinearelatedneurotoxicityinapediatricpatientwithsteroidresistantnephroticsyndrome
AT kalondabradshaw firstknowncaseofcatatoniaduetocyclosporinearelatedneurotoxicityinapediatricpatientwithsteroidresistantnephroticsyndrome
AT chadiacalarge firstknowncaseofcatatoniaduetocyclosporinearelatedneurotoxicityinapediatricpatientwithsteroidresistantnephroticsyndrome